Methods	O
:	O
In	O
this	O
prospective	O
,	O
open	O
-	O
label	O
,	O
randomized	O
and	O
double	O
blind	O
clinical	O
trial	O
,	O
100	O
patients	O
hospitalized	O
with	O
COVID	O
-	O
19	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
allocation	O
from	O
May	O
21	O
to	O
June	O
20	O
,	O
2020	O
,	O
to	O
either	O
standard	O
medical	O
treatment	O
(	O
Hydroxychloroquine	O
)	O
or	O
colchicine	O
with	O
standard	O
medical	O
treatment	O
.	O

The	O
study	O
took	O
place	O
in	O
Imam	O
Reza	O
hospital	O
of	O
Ardabil	O
city	O
in	O
Iran	O
,	O
with	O
trial	O
registration	O
ID	O
:	O
47707	O
(	O
irct	O
.	O
ir	O
)	O
.	O

Colchicine	O
group	O
were	O
received	O
1	O
mg	O
tablet	O
of	O
colchicine	O
daily	O
alongside	O
the	O
Hydroxychloroquine	O
for	O
6	O
days	O
.	O

Primary	O
end	O
points	O
were	O
(	O
1	O
)	O
Length	B-PrimaryOutcome
of	I-PrimaryOutcome
hospitalization	I-PrimaryOutcome
;	O
(	O
2	O
)	O
symptoms	B-PrimaryOutcome
and	O
(	O
3	O
)	O
Co	B-PrimaryOutcome
-	I-PrimaryOutcome
existed	I-PrimaryOutcome
disease	I-PrimaryOutcome
.	O

Secondary	O
end	O
points	O
were	O
examined	B-TimeFrame
2	I-TimeFrame
weeks	I-TimeFrame
after	I-TimeFrame
discharge	I-TimeFrame
and	O
included	O
(	O
1	O
)	O
mortality	B-SecondaryOutcome
and	I-SecondaryOutcome
morbidity	I-SecondaryOutcome
;	O
(	O
2	O
)	O
re	B-SecondaryOutcome
-	I-SecondaryOutcome
admission	I-SecondaryOutcome
and	O
(	O
3	O
)	O
symptoms	B-SecondaryOutcome
.	O

